AG1343 HIV protease inhibitor data

AGPH (La Jolla, Calif.) presented preliminary results from an ongoing pilot Phase II trial in the U.K. The lowest dose to be tested, 300 mg, showed a reduction in HIV in blood and an increase in CD4 counts. ...